![Magda Buttiens](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Network origin in Magda Buttiens first degree
Entity | Entity type | Industry | |
---|---|---|---|
Medinvents NV
![]() Medinvents NV Medical SpecialtiesHealth Technology Medinvents NV engages in the manufacture of biopsy surgical instruments. The company was founded on December 28, 1992 and is headquartered in Hasselt, Belgium.
3
| Private Company | Medical Specialties | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Magda Buttiens via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal | |
TIGENIX NV | Medical Specialties | Public Communications Contact | |
Ghent University | College/University | Doctorate Degree | |
Hasselt University | College/University | Doctorate Degree | |
Apitope Technology (Bristol) Ltd.
![]() Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Miscellaneous Commercial Services | Director/Board Member | |
SEPS Pharma NV
![]() SEPS Pharma NV Pharmaceuticals: GenericHealth Technology SEPS Pharma NV provides controlled drug delivery and develops self emulsifying pro drug systems. Its services include preformulation, formulation development and analytical development. The company was founded on October 19, 2007 and is headquartered in Diepenbeek, Belgium. | Pharmaceuticals: Generic | Director/Board Member | |
Life Sciences Consultancy | Founder | ||
Life Sciences Development Campus NV
![]() Life Sciences Development Campus NV Miscellaneous Commercial ServicesCommercial Services Life Sciences Development Campus NV provides research and development services in the field of biomedical life sciences. The company is headquartered in Abis, BelGium. | Miscellaneous Commercial Services | Chief Executive Officer |
Statistics
International
Belgium | 6 |
United States | 3 |
United Kingdom | 3 |
Netherlands | 2 |
Sectoral
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 3 |
Finance | 2 |
Operational
Director/Board Member | 7 |
Doctorate Degree | 2 |
Founder | 2 |
Corporate Officer/Principal | 1 |
Public Communications Contact | 1 |
Most connected contacts
Insiders | |
---|---|
Kris Motmans | 12 |
Jean-Pierre Grootaers | 1 |
Johan Janssens | 1 |
- Stock Market
- Insiders
- Magda Buttiens
- Company connections